EMAS position statement: Predictors of premature and early natural menopause


School of Public Health, Faculty of Medicine, University of Queensland, Brisbane 4006, Australia
Department of Pediatrics, Obstetrics and Gynecology, University of Valencia and INCLIVA, Valencia, Spain
Instituto de Investigación e Innovación en Salud Integral (ISAIN), Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador
Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece
Nantes, France Polyclinique de l’Atlantique Saint Herblain, F 44819 Saint Herblain, France
Université de Nantes F 44093 Nantes Cedex, France
University Women’s Hospital of Tuebingen, Calwer Street 7, 72076 Tuebingen, Germany
Women’s Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK
Istanbul University Cerrahpasa School of Medicine, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, IVF Unit, Istanbul, Turkey
Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy
National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London SW3 6NP, UK
Department of Obstetrics and Gynecology, University Women’s Hospital, Bern, Switzerland
Helsinki University and Helsinki University Hospital, Jula Hospital, Helsinki, Finland
Second Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Greece

ARTICLE INFO

Keywords:
- Early menopause
- Premature ovarian insufficiency
- Risk factors
- Aetiology

ABSTRACT

Introduction: While the associations of genetic, reproductive and environmental factors with the timing of natural menopause have been extensively investigated, few epidemiological studies have specifically examined their association with premature (< 40 years) or early natural menopause (40–45 years).

Aim: The aim of this position statement is to provide evidence on the predictors of premature and early natural menopause, as well as recommendations for the management of premature and early menopause and future research.

Materials and methods: Literature review and consensus of expert opinion.

Results and conclusions: Strong genetic predictors of premature and early menopause include a family history of premature or early menopause, being a child of a multiple pregnancy and some specific genetic variants. Women with early menarche and nulliparity or low parity are also at a higher risk of experiencing premature or early menopause. Cigarette smoking (with a strong dose–response effect) and being underweight have been consistently associated with premature and early menopause. Current guidelines for the management of premature and early menopause mainly focus on early initiation of hormone therapy (HT) and continued treatment until the woman reaches the average age at menopause (50–52 years). We suggest that clinicians and health professionals consider the age at menopause of the relevant region or ethnic group as part of the assessment for the timing of HT cessation. In addition, there should be early monitoring of women with a family history of early menopause, who are a child of a multiple pregnancy, or who have had early menarche (especially those who have had no children). As part of preventive health strategies, women should be encouraged to quit smoking (preferably before the age of 30 years) and maintain optimal weight in order to reduce their risk of premature or early menopause.

*Corresponding author.
E-mail address: g.mishra@sph.uq.edu.au (G.D. Mishra).

https://doi.org/10.1016/j.maturitas.2019.03.008

0378-5122/ © 2019 Elsevier B.V. All rights reserved.
1. Introduction

Timing of menopause is an indicator of ovarian function and has important health implications. Natural menopause is commonly defined as the time when a woman has experienced 12 consecutive months of amenorrhoea without obvious cause [1], such as removal of both ovaries (bilateral oophorectomy), chemotherapy or radiotherapy for cancer. The International collaboration on the Life course Approach to reproductive health and Chronic disease Events (InterLACE) [2] recently reported that the average age at natural menopause across 21 studies from 10 countries ranged from 47 to 53 years, varying across ethnic groups from 48 years for women of South Asian background to 50 years for Caucasian women living in Australia and Europe, and 52 years for Japanese women [3]. These results are primarily obtained from women living in high-income countries, hence the average age at menopause for women in low- and middle-income countries may lie outside this range.

Menopause before the age of 40 is commonly referred to as premature menopause, although primary ovarian insufficiency (POI) is currently considered the most apposite term to denote the loss of ovarian function as it does not specify definitive failure [4]. Menopause that occurs between 40 and 45 years is termed early menopause. Data from the InterLACE consortium indicate that in the general female population, the prevalence of premature menopause is 2% (range 1–3%) and of early menopause is 7.6% (range 5–10%), suggesting that almost one in 10 women have premature or early menopause [5]. Recent reviews have concluded that premature or early menopause is associated with an increased risk of all-cause mortality, cardiovascular disease, type 2 diabetes, depression, osteoporosis and fracture [6–11]. There is some evidence that premature menopause is associated with greater than average cognitive decline in later life [12], but current studies do not support a consistent association between early menopause and dementia risk [13].

Premature menopause is often idiopathic, but there are some genetic and autoimmune links, with X chromosome defects being the most common genetic contributors [14]. Few epidemiological studies have specifically examined the associations of non-genetic factors with premature and early menopause [5,15,16]. This position statement highlights the genetic, reproductive, lifestyle, and early-life and social/environmental factors associated with premature and early natural menopause. As findings in relation to premature menopause are limited, we focus on early menopause but include evidence specific to premature menopause where it is available.

2. Risk factors for premature and early natural menopause

2.1. Genetic factors

2.1.1. Heritability

Heritability estimates of age at menopause in mothers, daughters and sisters provide evidence for the contribution of genetic factors to the timing of menopause. The Framingham Heart Study reported that the heritability estimate for the adjusted age at natural menopause for the pooled sample of original and offspring cohorts was 0.52 [17]. This suggests that genetic effects explain at least half of the inter-individual variation in age at natural menopause. Cross-national heritability estimates for age at menopause of twin sisters range from 0.31–0.53 in an Australian sample [18], 0.63 in a UK sample [19], to 0.71–0.72 in a Dutch sample [20]. Mother–daughter pair data from the Netherlands give a heritability estimate of 0.44 [21].

2.1.2. Family history

Since genetic factors explain a substantial proportion of the variability in age at natural menopause, family history may be an important predictor of age at menopause. Early menopause (≤45 years) in a mother, sister, aunt or grandmother was associated with six-fold increased odds (OR 6.1, 95% CI 4.0–9.3) of early menopause after adjustment for smoking, education, parity and body mass index [22]. The risk of early menopause was strongest among women with a sister or multiple relatives with early menopause (9- to 12-fold increased odds) and those who had premature menopause (i.e. ≤40 years) (8-fold increased odds).

2.1.3. Multiple pregnancy

Twin registries in the UK and Australia indicate that twins have a significantly higher prevalence of POI than the general population, with a 3-fold and a 5-fold greater prevalence at the 40-year and 45-year thresholds [23]. Although the prevalence of POI in monozygotic (identical) and dizygotic (non-identical) twins was similar, ages at menopause were more concordant among monozygotic than among dizygotic twins. If one twin experienced menopause before age 40, her identical sister was almost seven times as likely to do so at the same age, confirming that the risk of POI has a strong heritable component. Findings from the UK Biobank have also shown that being a child of a multiple pregnancy was associated with a 50% increased likelihood of early menopause, after adjusting for early-life risk factors, including maternal smoking, birthweight, age at menarche, having breastfed as a baby and body composition at the age of 10 years [24].

It has been hypothesised that poor intrauterine growth, manifested as low birthweight, may lead to a decreased peak number of primordial follicles, which in turn may be associated with earlier menopause in adult life [25]. Foetal growth restriction, however, has not been found to restrict ovary growth and development [26]. Studies of twins have shown no significant association between difference in birthweight and difference in age at menopause in either monozygotic or dizygotic twin pairs [23,25]. Instead, there was some indication that twins with POI were heavier at birth than twins with normal or later age at menopause [25]. Further research is needed to explore the mechanisms underlying the higher risk of POI among twins.

2.1.4. Genetic variants

A recent meta-analysis of 22 genome-wide association studies (GWAS) with nearly 40,000 women of European ancestry confirmed the four previously established loci related to age at natural menopause, on chromosomes 5, 6, 19 and 20 [27,28], and identified 13 new loci [29]. Candidate genes located at or near identified loci include genes implicated in DNA repair (EXO1, HELQ, UIMC1, FAM175A, FANCJ, TLK1, POLG and PRIM1), immune function (IL11, RELP and PRRC2A) and hormone regulation (FSHB, STAR and BCAR4) [29]. In addition, several genes (WNT4, RSPO1, FOXL2 and BRCA2) critical for ovarian development and function have been identified [30,31], though further research is required to better understand their role in maintaining ovarian identity. However, previous GWAS excluded women with menopause before the age of 40 years [27,28]. The Breakthrough Generations Study (BGS) selected four common single-nucleotide polymorphisms (SNPs) at the four established loci and tested the associated risk of early menopause (≤45 years) [32]. All four SNPs were associated with an increased risk of early menopause (either including or excluding menopause before age 40), but the study was not sufficiently powered to detect the association with POI itself. The results suggest that genetic variants associated with the timing of menopause are also significant risk factors for early menopause [32]. Recent genetic studies have identified several genetic variants associated with POI, but results are conflicting [33,34] and many of these studies have methodological flaws and are underpowered [34].

2.2. Reproductive factors

2.2.1. Age at menarche

The timing of puberty has been linked to age at natural menopause. Findings from InterLACE with pooled data from over 50,000 post-menopausal women from nine studies in the UK, Scandinavia, Australia
and Japan have shown that women with early menarche (< 11 years) and Japan have shown that women with early menarche (< 11 years) and early menopause (relative risk (RR) 1.80, 95% confidence interval (CI) 1.53–2.12) and early menopause (RR 1.31, 95% CI 1.19–1.44), compared with those who had menarche at 13 years [5]. Data from the Nurses’ Health Study II (NHS II) (n = 108,811) [35] and the China Kadoorie Biobank (n = 17,076) [36] also showed that early menarche was associated with premature and early meno-pause in American and Chinese women respectively, though the defi-nition of early menarche was different (< 9 years versus 12 years in the NHS II, and ≤ 12 years versus 15 years in the China Biobank study). Furthermore, a case-control analysis of 11,781 cases of early meno-pause (< 45 years) and 173,641 controls (who had menopause or were still premenopausal at 45 years or over) in the UK Biobank identified an association between earlier age at menarche and early menopause [24].

2.2.2. Parity

Nulliparity has also been associated with earlier onset of natural menoopause [37,38], while higher parity has been reported to be related to later age at menopause [39]. The InterLACE consortium used in-dividual-level pooled data to show that nulliparity was associated with an increased risk of premature menopause (RR 2.26, 95% CI 1.84–2.77) and early menopause (RR 1.32, 95% CI 1.09–1.59) [5]. Furthermore, nulliparity strengthened the association between early menarche and the risk of premature and early menopause, with women who had early menarche and nulliparity having a 5-fold increased risk of premature menopause and a 2-fold risk of early menopause. Findings from the China Kadoorie Biobank also suggested that lower parity and older age at first birth were associated with early menopause [36].

On the other hand, premature or early menopause is an important indicator of ovarian hormone deficiency and infertility in young women [40,41]. Women with POI do not respond to traditional fertility treat-ments. Thus, their options for having children may be limited to adoption, donor embryo or egg donation with the use of in vitro fertilisation (IVF) [41]. However, up to 25% of women with POI may spontaneously ovulate, and they still have a 5–10% chance to conceive following diagnosis, and approximately 80% of the reported pregnan-cies have resulted in a healthy birth [42,43]. There is no secular trend of a decrease in age at menopause in recent decades, even though the average parity in developed countries has progressively dropped over this period [3]. Therefore, the potential confounding role of infertility or subfertility in the association between parity and age at menopause should be considered.

2.2.3. Characteristics of the menstrual cycle

Some evidence from a large prospective study has shown that length and regularity of early-life menstrual cycles may be early indicators of age at menopause. The NHS II study (n = 108,811) found that short menstrual cycles (< 25 days versus 26–31 days) and very regular cycles (± 3 days versus always irregular/no periods) at ages 18–22 years were strongly associated with a higher risk of early menopause (< 45 years) [35]. It also found that women with shorter and more regular cycles had lower levels of premenopausal anti-Müllerian hormone (AMH), a biomarker of ovarian reserve. The possible role of polycystic ovarian syndrome (PCOS) and the use of oral contraceptives (OC) might have confounded the findings. Assessment for PCOS and of OC use re-lated to menstrual cycle irregularities should be considered for future studies [35].

2.3. Lifestyle factors

2.3.1. Cigarette smoking

Among the lifestyle factors studied, cigarette smoking has been the most consistently linked to earlier age at natural menopause [44–48]. A meta-analysis of 15 studies showed that smoking was associated with an almost one year earlier age at natural menopause [45]. Smoking is thought to have an anti-oestrogenic effect, in part due to the increased production of adrenal androgens, which resists or blunts the functions of oestrogens [49,50]. Furthermore, cigarette smoking results in de-creased oestrogenic efficacy, due to the fast hepatic clearance of oral oestrogens among smokers [51]. In other words, smoking can jeo-pardise the success of oral hormone therapy.

A pooled analysis of 17 studies from InterLACE consortium (n = 207,231) found that current smokers were at twice the risk of premature menopause (< 40 years) and had an 80% increased risk of early menopause (40–44 years) compared with never smokers [15]. Even former smokers were at a higher risk of premature and early menopause, but to a much lesser extent, with risk increased by around 10–15%. This study found sig-nificant dose–response associations in both current and former smokers, in that higher intensity, longer duration, higher cumulative dose, ear-lier age of initiation and shorter time since quitting smoking were all associated with higher risks of premature and early menopause. Among these factors, the duration of smoking was the strongest predictor. Smokers who had quit for more than 10 years had a similar risk as never smokers, highlighting the clear benefits of early smoking cessation (preferably before the age of 30 years) for decreasing the risk of pre-mature or early menopause [15].

2.3.2. Body mass index

Body size and fat distribution have been considered in relation to the timing of menopause. Higher peripheral production of oestrone in the adipose tissue of obese women is hypothesised to contribute to a later onset of menopause [52]. In addition, adipose tissue functions as a specialised endocrine and paracrine organ that produces an array of adipokines, including leptin. It is known that leptin can act centrally at the hypothalamus and pituitary and peripherally at the ovary and re-productive tract, and thereby contribute to maintaining normal re-productive function [53,54]. In contrast, being underweight may trigger early menopause as a result of malnutrition, over-exercising, weight-loss diet and having concurrent or a history of chronic illness (e.g. chronic obstructive pulmonary disease) [55–57]. In addition, less adipose tissue leads to lower leptin levels, which have been associated with early menopause (< 45 years) [58].

A meta-analysis of nine observational studies with a total of 313,482 women found that being underweight was associated with earlier age at menopause, whereas being overweight or obese was associated with later age at menopause [52]. Recently, two large prospective studies showed a J-shaped relationship between body mass index (BMI) and the risk of early menopause (< 45 years) [16,59]. A pooled analysis of 11 prospective studies from the InterLACE consortium (n = 24,196) found that underweight women had over twice the risk of early menopause, and the risk remained after adjusting for smoking status [16]. To minimise the influence of weight change during the menopausal tran-sition, a sensitivity analysis was performed, examining the association for women who experienced onset of menopause at least five years after the collection of baseline BMI data. The associations of underweight and overweight/obesity with the risk of early menopause remained or even strengthened, suggesting that the effect of BMI may have been partly attenuated by baseline BMI recorded in the perimenopausal period [16]. The NHS II (n = 78,759) reported similar results, though the effect of being underweight on risk of early menopause was slightly attenuated and was not significant among non-smokers [59]. Further-more, weight change between early and middle adulthood seemed to be associated with early menopause. Women who lost 20 or more pounds from age 18 to 35 had a higher risk of early menopause than women who gained 5.1–15 pounds, though after adjustment for reproductive factors the risk was attenuated and no longer significant [59].

2.4. Early-life and social/environmental factors

Table 1 gives an overview of the genetic, reproductive, lifestyle, and early-life and social/environmental risk factors for premature and early menopause. While evidence has shown that early-life circumstances
and social/environmental factors are associated with the timing of natural menopause, almost no findings have been reported in relation to premature or early menopause. Nevertheless, it is still worthwhile to review the body of evidence that points to a cumulative effect on age at menopause of adverse exposures in early life and childhood, and of social/environmental conditions in early adulthood.

### 2.4.1. Birthweight, childhood growth and early-life nutrition

In a recent systematic review of 11 studies [60], nine reported no association between low birthweight and age at natural menopause, while three studies reported an association of higher birthweight and of higher ponderal index [birthweight/height$^3$ (kg/m$^3$)] with earlier age at menopause [61,62]. It is thought that women of lower socio-economic status are exposed to dietary deprivation, particularly during childhood [63]. There was evidence of an association between earlier age at natural menopause and prenatal and childhood famine (partially for severe famine experienced between the ages of 2 and 6 years) [64,65], low bodyweight (at age 1 or 2 years) [61,66,67] and not particularly for severe famine experienced between the ages of 2 and 6 years [61,65]. Low birthweight has been found to have a greater impact on age at natural menopause than those whose parents did not divorce, highlighting the possibility that early emotional stress may be a contributing factor. However, the findings suggest that poor early-life nutrition and poor childhood growth may influence the timing of menopause.

### 2.4.2. Childhood socioeconomic status

There is accumulating evidence that early-life socioeconomic circumstances influence reproductive health across the life course [24,68,69]. Adverse socioeconomic circumstances in childhood have been found to have a greater impact on age at natural menopause than the experience of such circumstances in adulthood [67,69,70]. The cumulative effect of childhood socioeconomic deprivation on age at menopause may be partly mediated by childhood nutrition, which influences both linear growth and age at menopause [70]. Cognitive function and early emotional stress may also be mediating factors related to this social gradient [69].

### 2.4.3. Childhood cognitive function

Cognitive function across the life course is associated with the timing of natural menopause, with the strongest effect found for childhood cognitive ability [71]. This suggests that ovarian steroids across the life course influence both neurodevelopment and the timing of menopause [71]. Evidence from two birth cohort studies in the UK showed that lower cognitive scores in childhood were associated with earlier age at menopause [72]. Furthermore, childhood intelligence was correlated with age at natural menopause, which may be attributed to both central neural mechanisms and the effects of childhood intelligence on general health in adulthood [73].

### 2.4.4. Childhood abuse

Early-life experience of violence may affect ovarian function and reproductive ageing via dysregulation of stress responses [74,75]. Women who experienced abuse during childhood or adolescence had more extreme levels of ovarian hormones during the menopausal transition, suggesting that early experience of abuse may lead to neuroendocrine disruption, which in turn affects ovarian function [75]. The Avon Longitudinal Study of Parents and Children found that childhood sexual abuse was associated with earlier age at menarche and menopause, but the finding for earlier age at menopause needs to be confirmed in studies with larger samples [76].

### 2.4.5. Parental divorce

A few studies have addressed the role of family structure and relationships in the timing of menopause. Women who experienced parental divorce before the age of five years tend to have earlier menopause than those whose parents did not divorce, highlighting the possibility that early emotional stress may be a contributing factor [68,69]. The effect of parental divorce was not weakened by adult socioeconomic status, smoking, parity, marital status or BMI, or by adult psychological events. This suggests that negative life events in childhood may have effects additional to those of disadvantage and poor health behaviours in adulthood [69]. Paternal absence, particularly for severe abuse was associated with earlier age at menarche and menopause, highlighting the additional effects of disadvantage and poor health behaviours in adulthood [69]. Paternal absence, particularly for severe abuse was associated with earlier age at menarche and menopause, but the finding for earlier age at menopause needs to be confirmed in studies with larger samples [76].

### 2.4.6. Education, occupation and income

A systematic review has suggested that there is some evidence that a
lower level of education is associated with earlier menopause, with 22
out of 29 studies finding a weak association (but for 10 studies it was
significant) [63]. A meta-analysis of 11 studies also showed that women
with a lower level of education experienced menopause 0.6 years ear-
lier than those with a high level and 0.3 years earlier than those with a
middle level of education [45]. A similar result was found for low oc-
cupational level, while there was no effect of income on age at meno-
pause. No evidence is available, however, regarding an association be-
 tween educational or occupational level and the risk of early meno-
pause. Mechanisms by which adverse socioeconomic conditions across
women’s lifespan relate to an early decline in ovarian function may
 involve exposures that influence the rate of oocyte depletion over the
life course [79].

2.4.7. Intimate-partner violence

A population-based cohort of 6000 midlife women in Australia
found that those who experienced intimate-partner violence were at
increased risk of early menopause (< 45 years) [80]. This association
remained after accounting for stress but was attenuated and no longer
significant after adjusting for smoking. The mediation analyses showed
that cigarette smoking explained 36.7% of the overall relationship be-
tween intimate-partner violence and early menopause after adjustment
for educational level, income difficulties and age at menarche. While
psychological stress may play a role in the timing of menopause, there
is not sufficient evidence to show that stress poses an additional risk of
early menopause.

3. Recommendations

Women with POI or early menopause experience an extended
period of time with loss of ovarian hormone activity, and have in-
creased risks of persistent vasomotor menopausal symptoms, cognitive
or affective disorders, heart disease, stroke, bone loss and overall
mortality [81]. The most recent recommendations are set out in the
2017 hormone therapy position statement of the North American Me-
opause Society (NAMS) [81]. This identifies women with POI or early
natural or induced menopause or who have had surgical menopause
before the age of 45 years, and particularly before the age of 40 years,
as being appropriate candidates for hormone therapy (HT). For these
women, the statement recommends early initiation of HT and its con-
tinued use at least until the median age of menopause (50–52 years),
unless contraindicated (for example, in women with hormone-sensitive
cancer). This is based on observational evidence on the prevention of
risks related to early oestrogen loss and adverse health outcomes.
Longer duration of HT may be considered for symptomatic women.
Younger women may require higher doses of HT for symptom relief or
protection against bone loss. The European Menopause and Andropause
Society (EMAS) position statement [82] and the NICE guideline [83]
also support this recommendation regarding HT use for women with
POI.

The evidence presented here has highlighted differences in age at
menopause across regional and ethnic groups (for some of these groups
it is less than 50 years). In addition, the current recommendations on
the use of HT by younger women are based on limited scientific evi-
dence [81,83]. Better-quality data are urgently needed to optimise the
management of young women with POI and early menopause and
thereby improve their short-term quality of life and long-term mor-
bidity and mortality [83]. Appropriate doses of HT, calcium and vi-
tamin D, adequate exercise, and screening to detect medical issues may
be effective in the management of women with POI or early menopause
[81]. It is also important to consider referring women with POI or early
menopause to specialists [83].

Since tests to predict age at menopause are lacking, family history
on age at menopause and reproductive and environmental risk factors
are important indicators to identify those women who are at increased
risk of premature or early menopause. Studies of gene–environment
interactions are warranted to unravel the complex interplay of genetic,
social and environmental factors associated with the risk of premature
and early menopause.

We make the following recommendations:

- clinicians and other health professionals should consider popula-
tion-specific age at menopause (including variations by ethnicity) as
part of the assessment for the timing of HT cessation;
- monitoring for early menopause should be offered to women with a
family history of early menopause, who are a child of a multiple
pregnancy or who experienced early menarche (particularly nulli-
parous women), as they are at substantially increased risk of pre-
mature and early menopause;
- preventive health strategies should be implemented to encourage
women to quit smoking (preferably before age 30) and maintain
optimal body weight, to lower their excess risk of premature and
early menopause.

4. Summary

- Premature menopause (also known as primary ovarian insufficiency
or POI) is defined as menopause before the age of 40, while early
menopause is defined as menopause between the ages of 40 and 45.
- Genetic factors contribute to around 50% of the variation in age at
natural menopause. A family history of premature or early meno-
pause, being a child of a multiple pregnancy and some specific ge-
etic variants have been identified as risk factors for premature and
early menopause.
- Early menarche, nulliparity or low parity, cigarette smoking and
being underweight are strong reproductive and lifestyle risk factors
associated with premature and early menopause.
- Current clinical guidelines for the management of premature and
early menopause focus on early initiation of HT and its continued
use until the average age of menopause (50–52 years for white
Western women).
- We suggest that the timing of HT cessation should account for the
age at menopause of the relevant ethnic or regional group rather
than assuming it is 50–52 years. In addition, we suggest there should
be early monitoring for women who have a family history of pre-
mature or early menopause, who are a multiple-birth child or who
had early menarche (especially nulliparous women) to prevent ad-
verse health outcomes associated with premature and early meno-
pause.
- More broadly, women should be encouraged to quit smoking (pre-
ferably before the age of 30 years) and maintain optimal weight to
reduce their risk of premature and early menopause.
- Further research is needed in the form of studies that have sufficient
statistical power to investigate premature and early menopause,
including, for example, the mechanisms behind the higher risk of
POI among twins, and the social and environmental factors that are
already known to increase the risk of earlier menopause.

Contributors

Gita D. Mishra and Hsin-Fang Chung prepared the initial draft,
which was circulated to all other named authors (EMAS board mem-
bers) for comments and approval; production was coordinated by Irene
Lambrinoudaki and Margaret Rees.

Conflict of interest

Gita D. Mishra, none declared.
Hsin-Fang Chung, none declared.
Antonio Cano, none declared.
Peter Chedraui, none declared.
Dimitrios G. Goulis, none declared.

86
Patrice Lopes, none declared.
Alfred Mueck, in the past 5 years, has received research funding from various pharmaceutical companies that produce and/or sell products used as hormone therapy in peri- and postmenopausal women; as well as lecture fees from various pharmaceutical companies for lectures on hormone therapy or other issues of menopause.

Margaret Rees has received consulting fees in the past 5 years from Metagenics.
Levent M. Senturk, none declared.
Tommaso Simoncini, in the past 5 years, has received consulting fees from Abbott, Actavis, Bayer and Estrella, as well as research support from Gedeon Richter.
John C. Stevenson, in the past 5 years, has received grants/research support from Abbott, Mylan and Pfizer, consulting fees from Abbott and Pfizer, and speakers’ honoraria from Agen, Bayer, Gedeon Richter, Menarini, Mylan and Theramex.
Petra Stute, in the past 5 years, has received grants/research support from Medinova AG and Dr Kade/Besins Pharma GmbH, and consulting fees from Max Zeller Söhne AG, Madaus.
Pauliina Tuomikoski, in the past 5 years, has received consulting fees and/or speakers’ honoraria from Abbott, Farmasian oppimiskeskus, Gedeon Richter, Mylan and Novo Nordisk, funding for congress trips from Mylan, and research grants from the Finnish Medical Association, 1,3 milj. klubi-klubben, the Päivikki and Sakari Sohlberg Foundation, and a special governmental grant for health sciences research.
Irene Lambrinoudaki, none declared.

Funding
No funding was received for the preparation of this position statement.

Ethical statement
No ethical approval was required for the preparation of this position statement.

Provenance and peer review
This article is an EMAS position statement and was not externally peer reviewed.

References